Spherix Inc (NASDAQ:SPEX) an intellectual property development company committed to the fostering and monetization of intellectual property, announced that Spherix and Charter Communications, Inc., Wideopenwest Finance LLC a/k/a Wow! Internet, Cable & Phone, Knology, Inc., Cequel Communications, LLC, d/b/a Suddenlink Communications, and Cable One, Inc., (collectively “Plaintiffs”) filed a joint stipulation of dismissal in the action filed on January 17, 2014. Spherix Inc (NASDAQ:SPEX) weekly performance is 2.75%. On last trading day company shares ended up $1.86. Analysts mean target price for the company is $1.00. Spherix Inc (NASDAQ:SPEX) distance from 50-day simple moving average (SMA50) is -2.55%.
On June 10, 2014, Endeavour International Corporation (NYSE:END) announced that it has received numerous calls from analysts and investors making inquiries regarding recent market activity in the Company’s stock. Management of the Company is unaware of any reason why recent trading of the stock has resulted in a significant decrease in its price over the last few days. Endeavour International Corporation (NYSE:END) shares advanced 4.49% in last trading session and ended the day on $1.86. Gross Margin is 69.20 % and its return on assets is -8.40%. Endeavour International Corporation (NYSE:END) quarterly performance is -55.08%.
On June 2, 2014, Galena Biopharma Inc (GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, announced that data from the Company’s Phase 1 study with GALE-301, or Folate Binding Protein (FBP), was presented at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting. Galena Biopharma Inc (NASDAQ:GALE) shares moved up 3.84% in last trading session and was closed at $3.25, while trading in range of $2.92 – $3.58. Galena Biopharma Inc (NASDAQ:GALE) year to date (YTD) performance is -34.48%.
Santander Consumer USA Holdings Inc (NYSE:SC) has received a consensus recommendation of “Buy” from the thirteen analysts that are covering the stock, Analyst Ratings.Net reports. Two equities research analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. Santander Consumer USA Holdings Inc (NYSE:SC) ended the last trading day at $19.25. Company weekly volatility is calculated as 4.33% and price to cash ratio as 59.52. Santander Consumer USA Holdings Inc (NYSE:SC) showed a negative weekly performance of -5.03%.
Orexigen® Therapeutics, Inc. (NASDAQ:OREX) announced that the United States Food and Drug Administration (FDA) has extended its review of the resubmitted New Drug Application (NDA) for NB32, the Company’s investigational medication being evaluated for weight loss. The new Prescription Drug User Fee Act (PDUFA) action date has been set for September 11, 2014. Orexigen Therapeutics, Inc. (NASDAQ:OREX) weekly performance is -5.07%. On last trading day company shares ended up $5.81. Analysts mean target price for the company is $11.63. Orexigen Therapeutics, Inc. (NASDAQ:OREX) distance from 50-day simple moving average (SMA50) is 0.76%.